IRIS
TARANTINO, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.363
NA - Nord America 2.044
AS - Asia 1.378
SA - Sud America 174
AF - Africa 51
OC - Oceania 5
Totale 6.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.995
RU - Federazione Russa 1.308
SG - Singapore 670
CN - Cina 313
HK - Hong Kong 288
IT - Italia 254
FI - Finlandia 186
DE - Germania 165
BR - Brasile 161
NL - Olanda 152
IE - Irlanda 99
UA - Ucraina 63
VN - Vietnam 44
CA - Canada 42
GB - Regno Unito 42
SE - Svezia 40
CI - Costa d'Avorio 34
FR - Francia 22
IN - India 13
TR - Turchia 13
ZA - Sudafrica 11
PL - Polonia 9
AT - Austria 6
AR - Argentina 5
BD - Bangladesh 5
IQ - Iraq 5
AU - Australia 4
BE - Belgio 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
MX - Messico 3
PK - Pakistan 3
AE - Emirati Arabi Uniti 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
EG - Egitto 2
ES - Italia 2
GR - Grecia 2
JO - Giordania 2
JP - Giappone 2
KR - Corea 2
LT - Lituania 2
UY - Uruguay 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
TG - Togo 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VA - Santa Sede (Città del Vaticano) 1
VE - Venezuela 1
Totale 6.015
Salva come PNG Salva come JPEG
Città #
Singapore 438
Moscow 342
Chandler 314
Hong Kong 288
Santa Clara 180
Amsterdam 134
Princeton 113
Jacksonville 97
Millbury 95
Nanjing 80
Boston 72
Napoli 67
Ashburn 48
Naples 48
Beijing 47
Des Moines 47
Dong Ket 44
Helsinki 37
Wilmington 37
Ottawa 33
Turku 31
Nanchang 29
Munich 28
Boardman 24
Shenyang 20
Hebei 19
São Paulo 19
Falkenstein 17
Seattle 17
The Dalles 15
Norwalk 14
Hefei 13
Tianjin 13
London 12
Los Angeles 12
Frankfurt am Main 11
Jiaxing 11
Rome 11
Changsha 10
Kunming 10
Falls Church 9
Kronberg 9
Lawrence 8
Malmo 8
Dearborn 7
Milan 7
Nuremberg 7
Belo Horizonte 6
Chicago 6
Dallas 6
New York 6
Toronto 6
Ankara 5
Brooklyn 5
Campinas 5
Catania 5
Dublin 5
Hangzhou 5
Washington 5
Fairfield 4
Köln 4
Melfi 4
Redwood City 4
Rio de Janeiro 4
Rochdale 4
San Francisco 4
Tashkent 4
Vitória da Conquista 4
Wroclaw 4
Annapolis 3
Augusta 3
Baku 3
Bexley 3
Brasília 3
Charlotte 3
Courcelles 3
Guarulhos 3
Johannesburg 3
Kochi 3
Lappeenranta 3
Nocera Inferiore 3
Oliveto Citra 3
Pune 3
Redmond 3
Shanghai 3
Vienna 3
Warsaw 3
Wuhan 3
Zhengzhou 3
Birmingham 2
Blumenau 2
Brisbane 2
Brno 2
Buenos Aires 2
Cairo 2
Caxias do Sul 2
Changchun 2
Cologne 2
Criciúma 2
Curitiba 2
Totale 3.139
Salva come PNG Salva come JPEG
Nome #
"obesity paradox" or "metabolically benign obesity"? 95
Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study 81
Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire 80
Incidence of hypertension in individuals with different blood pressure salt-sensitivity: results of a 15-year follow-up study. 80
Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population. 79
EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. 78
Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation 76
Abnormally high resistive index of central retinal artery by ultrasound color Doppler in patients with viral chronic liver disease: correlation with worsening liver staging. 75
Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors 75
A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient 73
A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. 72
Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Patients: A Novel Association 72
Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. 71
Long-term assessment of plasma lipids in transplant recipients treated with tacrolimus in relation to fatty liver. 71
Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved? 70
BISPHENOL A IN POLYCYSTIC OVARY SYNDROME AND ITS ASSOCIATION WITH LIVER-SPLEEN AXIS. 70
UCP1 -3826 AG+GG genotypes, adiponectin, and leptin/adiponectin ratio in severe obesity. 68
A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer 67
Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients 67
Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. 67
ARE HEPATIC STEATOSIS AND CAROTID INTIMA MEDIA THICKNESS ASSOCIATED IN OBESE PATIENTS WITH NORMAL OR SLIGHTLY ELEVATED GAMMA-GLUTAMYL-TRANSFERASE? 67
Hematocrit Values Predict Carotid Intimal-Media Thickness in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study 67
Hepatic steatosis, carotid plaques and achieving MDA in psoriaticarthritis patients starting TNF-alpha blockers treatment: a prospective study. 66
Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease 66
Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients 65
Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study 65
Aspetti psico-sociali delle malattie allergiche 63
Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease. 63
Circulating levels of sirtuin 4, a potential marker of oxidative metabolism, related to coronary artery disease in obese patients suffering from nafld, with normal or slightly increased liver enzymes 62
Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? 61
Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. 61
Enhanced serum concentrations of transfroming growth factor-beta 1 in simple fatty liver: it is really benign? 61
Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. 61
Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with nonalcoholic fatty liver disease 61
Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. 60
Analysis of extracellular superoxide dismutase in fibroblasts from patients with systemic sclerosis 60
Successful and safe long-term standard antiviral therapy in a patient with “Explosive” immune response in course of HCV-related liver cirrhosis 60
Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration 60
Should octreotide be used cautiously in liver cirrhosis with concomitant congestive heart failure correlated to coronary artery disease? 59
Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study 59
Exaggerated immune reactions predict the outcome of interferon therapy in patients with chronic hepatitis C. 58
The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome. 58
Comparison of the everolimus concentrations measured in whole blood with everolimus QMS or sirolimus CMIA 58
Is serum Interleukin-17 associated with early atherosclerosis in obese patients? 57
Drug-induced liver injury due to "natural products" used for weight loss: a case report. 56
What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis? 55
Exposure to ambient air particulate matter and non-alcoholic fatty liver disease 55
Epatopatia e coagulazione 54
Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie's disease and are there any implications for a better understanding of its mechanisms? 54
Could inflammatory markers help diagnose nonalcoholic steatohepatitis? 53
Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation 53
Silent non-alcoholic fatty liver disease - A clinical-histological study 52
Extensive psoriasis induced by pegylated interferon: a case report. 51
Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy. 51
Rheumatoid factor after antiviral therapy in patients with HCV chronic hepatitis. 51
What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? 51
Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. 50
Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease 50
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? 50
Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis? 49
Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity? 49
Liver-spleen axis: Intersection between immunity, infections and metabolism 48
Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis 48
Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. 48
Does spleen volume play a role in patients with HCV-related chronic hepatitis? 47
Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand? 47
What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? 47
Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms 47
Nutrition, inflammation and liver-spleen axis 47
Utility of sonography in diagnosing hepatocellular carcinoma 46
Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. 46
From bed to bench: which attitude towards the laboratory liver tests should health care practitioners strike? 45
Successful lamivudine monotherapy in an elderly patient suffering from HBV-related decompensated cirrhosis associated with widespread leukocytoclastic vasculitis. 45
Hepatic steatosis in overweight/obese females: new screening method for those at risk 44
What non-alcoholic fatty liver disease has got to do with obstructive sleep apnoea syndrome and viceversa? 44
Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. 43
Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist? 43
Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? 43
Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review 42
Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? 42
Pathogenesis of hepatic steatosis: The link between hypercortisolism and non-alcoholic fatty liver disease 42
Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease 41
Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status 41
Circulating levels of interferon-gamma in course of hepatitis C virus-related arthritis. 40
Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis 39
Could quantitative liver function tests gain wide acceptance among hepatologists? 39
Inhibition of the mTOR pathway: A possible protective role in coronary artery disease 39
Non-alcoholic fatty liver disease, obesity and other illnesses. 38
Should visceral fat be reduced to increase longevity? 37
Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism 37
Positivity for anti-HCV antibodies among Italian hospitalized patients 36
Relationship between growth hormone (GH)/insulin-like growth factor (IGF)-1 status and hepatic steatosis in overweight-obese women. 36
Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance 35
New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants 34
Insulin-like Growth Factor-1, Psoriasis, and inflammation: a mènage a trois 33
Is the quality of life always depressed in patients with chronic hepatitis C on antiviral therapy? 33
Steatosis, steatohepatitis and cancer immunotherapy: An intricate story 33
Serum 25-Hydroxyvitamin D Levels, Phosphoprotein Enriched in Diabetes Gene Product (PED/PEA-15) and Leptin-to-Adiponectin Ratio in Women with PCOS. 32
Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. 32
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? 32
Totale 5.440
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.128
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.128
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202042 0 0 0 0 0 0 0 0 0 0 0 42
2020/2021219 0 13 18 16 19 42 23 2 17 6 18 45
2021/2022610 3 1 7 1 4 23 7 22 102 24 154 262
2022/2023785 124 69 30 39 77 76 1 67 117 121 46 18
2023/2024535 25 106 78 33 20 22 10 49 5 12 111 64
2024/20253.204 187 204 12 34 82 220 326 225 190 345 1.265 114
Totale 6.189